Gene editing has always had a size problem. The molecular scissors that scientists use to cut and repair DNA — the CRISPR-Cas ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...

“It’s something we need to pay attention to, especially as CRISPR expands to more diseases,” Sam Kulkarni, the CEO of CRISPR Therapeutics, which was not involved with either study, tells STAT News.

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...